JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (3): 386-390.doi: 10.3969/j.issn.1674-8115.2021.03.018

• Review • Previous Articles     Next Articles

Progress in researches on improving engraftment of hematopoietic stem/progenitor cells of cord blood

Liu-xin NING(), Si-guo HAO()   

  1. Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Received:2020-01-15 Online:2021-03-28 Published:2021-04-06
  • Contact: Si-guo HAO;
  • Supported by:
    Three-year Action Plan for Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shenkang Hospital Development Center(16CR1033B)


Cord blood transplantation (CBT) has been widely used in the treatment of hematologic malignancies and non-malignant hematologic diseases both in children and adults. Compared with other sources of hematopoietic stem/progenitor cell (HSPC) transplantation, CBT has a higher rate of engraftment failure and delayed hematopoietic system and immune system recovery, thereby increasing the mortality caused by infection and other transplant-related complications. Therefore, how to promote the engraftment of cord blood HSPC has been a hot spot in CBT for many years. The article reviews the latest advances in the strategies to improve the engraftment of HSPC of cord blood.

Key words: cord blood transplantation (CBT), hematopoietic stem/progenitor cell (HSPC), in vitro expansion, engraftment, homing

CLC Number: